TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

EORTC 10994/BIG 1-00 Study Investigators; Hervé Bonnefoi; Martine Piccart; Jan Bogaerts; Louis Mauriac; Pierre Fumoleau; Etienne Brain; Thierry Petit; Philippe Rouanet; Jacek Jassem; Emmanuel Blot; Khalil Zaman; Tanja Cufer; Alain Lortholary; Elisabet Lidbrink; Sylvie André; Saskia Litière; Lissandra Dal Lago; Véronique Becette; David A Cameron; Jonas Bergh; Richard Iggo

doi:10.1016/S1470-2045(11)70094-8

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

EORTC 10994/BIG 1-00 Study Investigators, Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, Louis Mauriac, Pierre Fumoleau, Etienne Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Khalil Zaman, Tanja Cufer, Alain Lortholary, Elisabet Lidbrink, Sylvie André, Saskia Litière, Lissandra Dal Lago, Véronique Becette, David A CameronJonas Bergh, Richard Iggo

Research output: Contribution to journal › Article › peer-review

Abstract

TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53.

Original language	English
Pages (from-to)	527-39
Number of pages	13
Journal	The Lancet Oncology
Volume	12
Issue number	6
DOIs	https://doi.org/10.1016/S1470-2045(11)70094-8
Publication status	Published - 2011

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Female
Humans
Middle Aged
Mutation
Neoadjuvant Therapy
Receptor, erbB-2
Receptors, Estrogen
Taxoids
Tumor Suppressor Protein p53

Access to Document

10.1016/S1470-2045(11)70094-8

Cite this

EORTC 10994/BIG 1-00 Study Investigators, Bonnefoi, H., Piccart, M., Bogaerts, J., Mauriac, L., Fumoleau, P., Brain, E., Petit, T., Rouanet, P., Jassem, J., Blot, E., Zaman, K., Cufer, T., Lortholary, A., Lidbrink, E., André, S., Litière, S., Lago, L. D., Becette, V., ... Iggo, R. (2011). TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. The Lancet Oncology, 12(6), 527-39. https://doi.org/10.1016/S1470-2045(11)70094-8

@article{87bdd17e1f424655af02d5d691dcfac8,

title = "TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial",

abstract = "TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoadjuvant Therapy, Receptor, erbB-2, Receptors, Estrogen, Taxoids, Tumor Suppressor Protein p53",

author = "{EORTC 10994/BIG 1-00 Study Investigators} and Herv{\'e} Bonnefoi and Martine Piccart and Jan Bogaerts and Louis Mauriac and Pierre Fumoleau and Etienne Brain and Thierry Petit and Philippe Rouanet and Jacek Jassem and Emmanuel Blot and Khalil Zaman and Tanja Cufer and Alain Lortholary and Elisabet Lidbrink and Sylvie Andr{\'e} and Saskia Liti{\`e}re and Lago, {Lissandra Dal} and V{\'e}ronique Becette and Cameron, {David A} and Jonas Bergh and Richard Iggo",

year = "2011",

doi = "10.1016/S1470-2045(11)70094-8",

language = "English",

volume = "12",

pages = "527--39",

journal = "The Lancet Oncology",

issn = "1474-5488",

publisher = "Lancet Publishing Group",

number = "6",

}

EORTC 10994/BIG 1-00 Study Investigators, Bonnefoi, H, Piccart, M, Bogaerts, J, Mauriac, L, Fumoleau, P, Brain, E, Petit, T, Rouanet, P, Jassem, J, Blot, E, Zaman, K, Cufer, T, Lortholary, A, Lidbrink, E, André, S, Litière, S, Lago, LD, Becette, V, Cameron, DA, Bergh, J & Iggo, R 2011, 'TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial', The Lancet Oncology, vol. 12, no. 6, pp. 527-39. https://doi.org/10.1016/S1470-2045(11)70094-8

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. / EORTC 10994/BIG 1-00 Study Investigators; Bonnefoi, Hervé; Piccart, Martine et al.
In: The Lancet Oncology, Vol. 12, No. 6, 2011, p. 527-39.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

AU - EORTC 10994/BIG 1-00 Study Investigators

AU - Bonnefoi, Hervé

AU - Piccart, Martine

AU - Bogaerts, Jan

AU - Mauriac, Louis

AU - Fumoleau, Pierre

AU - Brain, Etienne

AU - Petit, Thierry

AU - Rouanet, Philippe

AU - Jassem, Jacek

AU - Blot, Emmanuel

AU - Zaman, Khalil

AU - Cufer, Tanja

AU - Lortholary, Alain

AU - Lidbrink, Elisabet

AU - André, Sylvie

AU - Litière, Saskia

AU - Lago, Lissandra Dal

AU - Becette, Véronique

AU - Cameron, David A

AU - Bergh, Jonas

AU - Iggo, Richard

PY - 2011

Y1 - 2011

N2 - TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53.

AB - TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Breast Neoplasms

KW - Female

KW - Humans

KW - Middle Aged

KW - Mutation

KW - Neoadjuvant Therapy

KW - Receptor, erbB-2

KW - Receptors, Estrogen

KW - Taxoids

KW - Tumor Suppressor Protein p53

UR - http://www.scopus.com/inward/record.url?scp=79957527931&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70094-8

DO - 10.1016/S1470-2045(11)70094-8

M3 - Article

C2 - 21570352

SN - 1474-5488

VL - 12

SP - 527

EP - 539

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Other files and links

Fingerprint

Cite this